3aZEVvoRtp6McXy8TuIlR6lERn067Z

Investor Relations

NYSE: NVRO

Price

87.72 -1.07 ( -1.21% ) 4:02 4/25/18 Pricing delayed 20 minutes

Volume

Recent News

See All
April 23, 2018 Nevro to Report Operating Results for the First Quarter 2018
Nevro to Host Conference Call on Monday, May 7, 2018 at 1:30 p.m. PT / 4:30 p.m. ET Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that it will release financial results for the first quarter of 2018 after market close on Monday, May 7, 2018 . Company management will host a conference call beginning at 1:30 p.m. Pacific Time ( 4:30 p.m. Eastern Time ) on Monday, May 7, 2018 . Investors interested in listening to the conference call may do so by dialing (866) 393-4306 for U.S. callers or (734) 385-2616 for international callers (Conference ID: 8882719), or logging into the webcast on the "Investors" section of the Company's website at www.nevro.com/investors. Following the call, a replay will be available on the Investor Events and Presentations webpage of the Company's website. About Nevro Headquartered in Redwood City, California, Nevro is a global medical device...
March 22, 2018 Full-Body MRI Conditional Labeling Now Available in United States for Nevro Senza® Spinal Cord Stimulation System
Expanding Patient Access to Nevro's HF10® Therapy Through Broader Imaging Compatibility Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today announced that full-body magnetic resonance imaging (MRI) conditional labeling is now available in the United States for the Senza Spinal Cord Stimulation (SCS) System delivering HF10 therapy. This labeling expansion, which is now applicable in all our markets, adds to the previous labeling allowing head and extremity MRI scans, broadening the pool of patients who are eligible to receive the Senza SCS System. This approval is retroactive, meaning that the new labeling for expanded imaging applies to all patients currently implanted with the Senza SCS System and percutaneous leads.  It is anticipated that a similar labeling expansion will follow for the Senza II SCS system. "Expanding full-body MRI conditional labeling is a significant milestone in...
February 22, 2018 Nevro Reports Fourth Quarter and Full Year 2017 Financial Results and Provides 2018 Outlook
Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative evidence-based solutions for the treatment of chronic pain, today reported financial results for the three months and full year ended December 31, 2017 . 2017 Accomplishment & Highlights: Achieved revenue of $326.7 million for the full year 2017, an increase of 43%, as reported, over the prior year U.S. revenue of $263.5 million for 2017, an increase of 52% over the prior year International revenue of $63.2 million for 2017, an increase of 13% in constant currency and 15% on an as-reported basis, both over the prior year Achieved positive EBITDA and operating cash flow for each of the third and fourth quarters of 2017, excluding litigation expense Received CE Mark for next generation Senza II Received CE Mark for Senza I Conditional Full Body MRI Initiated Randomized Controlled Trials (RCT) in two new indications Presented positive clinical trial results during the 16 th Annual Pain Medicine...

About Nevro

Headquartered in Redwood City, California, Nevro is a global medical device company focused on providing innovative products that improve the quality of life of patients suffering from debilitating chronic pain. Nevro has developed and commercialized the SENZA® spinal cord stimulation (SCS) system, an evidence-based, non-pharmacologic neuromodulation platform for the treatment of chronic pain. The SENZA® system is the only SCS system that delivers Nevro's proprietary HF10™ therapy. Senza, Senza II, HF10, Nevro and the Nevro logo are trademarks of Nevro.

Senza, HF10, Nevro, and the Nevro logo are trademarks of Nevro Corp.